Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Candel Therapeutics

Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Upcoming Investor Conference Participation for November
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
From Candel Therapeutics
Via GlobeNewswire
Tickers CADL
Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
From Candel Therapeutics
Via Business Wire
Candel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader
From Candel Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.